EDESA BIOTECH INC. news, videos and press releases
For more news please use our advanced search feature.
EDESA BIOTECH INC. - More news...
EDESA BIOTECH INC. - More news...
- Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
- Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
- Edesa Biotech to Participate in Upcoming Investor Conferences
- Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
- Edesa Biotech to Participate in Barclays Global Healthcare Conference
- Edesa Biotech to Participate in Upcoming Dermatology Meetings
- Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
- Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
- Edesa Biotech Reports Fiscal Year 2023 Results
- Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
- Edesa Biotech to Present at Dermatology Drug Development Summit
- Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
- Edesa Biotech Secures $10 Million Credit Facility with Company Founder
- Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
- Edesa Biotech Announces One-for-Seven Reverse Share Split
- Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
- Edesa Biotech Reports Fiscal Third Quarter 2023 Results
- Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
- Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
- Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
- Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
- Edesa Biotech to Participate in Swiss Biotech Day
- The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
- Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
- Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
- Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
- Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
- Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
- Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
- FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
